Praxis Precision Medicines, Inc. (PRAX)
- Previous Close
47.46 - Open
45.95 - Bid 45.69 x 100
- Ask 46.02 x 100
- Day's Range
45.28 - 48.00 - 52 Week Range
12.60 - 67.21 - Volume
103,511 - Avg. Volume
266,885 - Market Cap (intraday)
784.483M - Beta (5Y Monthly) 2.88
- PE Ratio (TTM)
-- - EPS (TTM)
-10.95 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
137.17
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
praxismedicines.comRecent News: PRAX
Performance Overview: PRAX
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRAX
Valuation Measures
Market Cap
811.94M
Enterprise Value
606.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
198.60
Price/Book (mrq)
3.54
Enterprise Value/Revenue
276.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.65%
Return on Equity (ttm)
-85.25%
Revenue (ttm)
2.19M
Net Income Avi to Common (ttm)
-125.38M
Diluted EPS (ttm)
-10.95
Balance Sheet and Cash Flow
Total Cash (mrq)
207.42M
Total Debt/Equity (mrq)
0.97%
Levered Free Cash Flow (ttm)
-56.28M